A Randomized Controlled Trial to Evaluate the Anti-inflammatory Effect of Commiphora Wightii in Combination with Curcuma Longa against Diclofenac Potassium in Non-specific Knee Effusion

Knee effusion is an abnormal accumulation of the fluid in the knee capsule or the adjoining supra-patellar bursa secondary to the irritation/inflammation in the joint synovium. It is seen in approximately 8-10 % of the total patients suffering from osteo-arthrosis. Kroṣṭukaśīrṣaas described in Ayurveda, can be corelated with knee effusion. In Present clinical trial an effort has been made to evaluate anti-inflammatory effect of Commiphora wightii in combination with Curcuma longa against Diclofenac potassium [NSAID’s] in Non-specific knee effusion. Total twenty two, clinically diagnosed patients of Non-specific knee effusion were selected for the present clinical trial excluding drop out 20 patients were assorted in to two groups Trial Group and control Groups. Trial Group 10 patients were given crude extract of Commiphora wightii 500 mg along with Curcuma longa 500 mg in a separate capsule twice a day continuously for 8 weeks orally. In Control Groupten patients were given Diclofenac Potassium 50 mg twice a day continuously for 2 weeks orally. It was assessed that Diclofenac potassium was significantly better in the outcomes in comparison to the trial drugs Commiphora wightii (Guggulu) and Curcuma longa (Haridra) when compared at the end of two weeks of start of the trial. Trial drugs Commiphora wightii (Guggulu) and Curcuma longa (Haridra) are also having outcomes of comparative extent to Diclofenac Potassium when administered continuously for further 6 weeks i.e. total 8 weeks.